本文選題：立體定向體部放射治療　切入點(diǎn)：非小細(xì)胞肺癌　出處：《鄭州大學(xué)》2017年碩士論文

【摘要】：目的本研究采用流式細(xì)胞術(shù)的方法,前瞻地研究接受SBRT早期及寡轉(zhuǎn)移肺癌患者治療前后外周血淋巴細(xì)胞亞群比例的變化,探討SBRT對(duì)早期非小細(xì)胞肺癌及寡轉(zhuǎn)移肺癌患者免疫功能的影響。材料與方法2015年10月至2017年1月,采集在河南省腫瘤醫(yī)院放療科接受SBRT的早期非小細(xì)胞肺癌及寡轉(zhuǎn)移肺癌22例患者,其中男18例,女4例;中位年齡74歲(48-84歲)。I期肺癌14例,寡轉(zhuǎn)移8例。放療前0-7天,放療后0-7天,放療后4周分別采集外周血(可與入組常規(guī)采血一同進(jìn)行),采用流式細(xì)胞術(shù)進(jìn)行淋巴細(xì)胞亞群檢測(cè):CD3+(總T細(xì)胞,Total T lymphocytes),CD3+CD4+(T輔助/誘導(dǎo)細(xì)胞),CD3+CD8+(T抑制/細(xì)胞毒性細(xì)胞),CD4+CD25+(調(diào)節(jié)性T細(xì)胞,Regulatory T lymphocytes,Treg),CD8+CD28-(抑制性T細(xì)胞,Suppressive T lymphocytes,Ts),CD8+CD28+(細(xì)胞毒性T細(xì)胞,Cytotoxic T lymphocytes,Tc),CD4+/CD8+(CD4+與CD8+亞群比值)。采用SPSS22.0軟件進(jìn)行統(tǒng)計(jì)學(xué)分析,分類變量由頻數(shù)和百分比描述。連續(xù)變量由平均數(shù)±標(biāo)準(zhǔn)差描述。采用配對(duì)t檢驗(yàn)對(duì)比治療前后自身淋巴細(xì)胞亞群比例的變化。P0.05為具有統(tǒng)計(jì)學(xué)差異。結(jié)果1.入組22例患者均放療前0-7天及放療后0-7天均進(jìn)行了淋巴細(xì)胞亞群檢測(cè),其中11例患者放療后4周進(jìn)行淋巴細(xì)胞亞群檢測(cè);2.22例患者放療前0-7天與放療后0-7天比,除CD3+放療后較放療前增加(P=0.023),其他淋巴細(xì)胞亞群比例變化不明顯(P0.05);3.11例患者放療后4周進(jìn)行淋巴細(xì)胞亞群檢測(cè),患者淋巴細(xì)胞亞群與放療之前淋巴細(xì)胞亞群比變化不明顯(P0.05),見(jiàn)表8;4.對(duì)于13例早期原發(fā)非小細(xì)胞肺癌患者,放療前0-7天與放療后0-7天比,各淋巴細(xì)胞亞群變化均不明顯(P0.05);5.對(duì)于9例肺部寡轉(zhuǎn)移患者,放療前0-7天與放療后0-7天比,CD3+放療后較放療前增加(P=0.027),CD3+CD4+放療后較放療前增加(P=0.038),CD4+CD25+放療后較放療前增加(P=0.032),其他淋巴細(xì)胞亞群比例變化不明顯(P0.05)。結(jié)論SBRT治療對(duì)于肺部腫瘤患者免疫功能影響不大,可以認(rèn)為對(duì)于因高齡或合并嚴(yán)重心、肺等內(nèi)科疾病不能或不愿接受手術(shù)的患者其是一種安全有效的治療手段。對(duì)于肺部寡轉(zhuǎn)移的患者,對(duì)其進(jìn)行SBRT治療后,可能會(huì)引起免疫功能改變,可能與局部免疫反應(yīng)有關(guān)。另外,SBRT治療可能引起腫瘤局部免疫反應(yīng),具體的檢測(cè)生物學(xué)標(biāo)記、檢測(cè)方法以及檢測(cè)時(shí)機(jī)有待進(jìn)一步研究。
[Abstract]:Objective to study the changes of lymphocyte subsets in peripheral blood of patients with early SBRT and oligometastasis lung cancer before and after treatment with flow cytometry. To investigate the effect of SBRT on immune function in patients with early non-small cell lung cancer and oligometastasis lung cancer. Materials and methods from October 2015 to January 2017, Twenty-two patients with early non-small cell lung cancer (NSCLC) and oligometastasis lung cancer (18 males and 4 females) received SBRT in radiotherapy Department of Henan Cancer Hospital, 14 patients with stage I lung cancer aged from 74 to 84 years old and 8 patients with oligometastases were enrolled. 0-7 days after radiotherapy, Four weeks after radiotherapy, peripheral blood was collected separately (which can be taken together with routine blood collection). The lymphocyte subsets were detected by flow cytometry. Total T lymphocytes were detected by total T lymphocyte lymphocyte subsets. CD3 CD8 T suppression / cytotoxicity was detected by T assisted / induced cells. The ratio of CD4 / CD8 CD25 (cytotoxic T lymphocytes) to CD _ 4 / CD _ 8 (CD _ 4 / CD _ 8 / CD8) subsets were analyzed by SPSS22.0 software, and the ratio of CD _ 4 / CD _ 8 / CD _ 8 / CD _ 8 / CD _ 8 / CD _ 8 / CD _ 8 / CD _ 4 / CD _ 8 / CD _ 4 / CD _ 8 / CD _ 4 / CD _ 8 / CD _ 4 / CD _ 8 / CD _ 4 / CD _ 8 / CD _ 4 / CD _ 8 subsets were analyzed by SPSS22.0 software. The classification variable is described by frequency and percentage. The continuous variable is described by mean 鹵standard deviation. The ratio of autologous lymphocyte subsets before and after treatment is compared by paired t test. Results 1. Lymphocyte subsets were detected 0-7 days before radiotherapy and 0-7 days after radiotherapy in 22 patients. Lymphocyte subsets were detected in 11 patients at 4 weeks after radiotherapy compared with 0-7 days before radiotherapy and 0-7 days after radiotherapy in 2.22 patients. The lymphocyte subsets were detected 4 weeks after radiotherapy in 3. 11 patients with CD3, except for the increase of P0. 023 after radiotherapy. The ratio of lymphocyte subsets to lymphocyte subsets before radiotherapy in 13 patients with early non-small cell lung cancer (NSCLC) was not significantly different from that before radiotherapy (P 0.05), as shown in Table 8 (4). For 13 patients with early non-small cell lung cancer (NSCLC), the ratio of 0 to 7 days before radiotherapy was higher than that of 0 to 7 days after radiotherapy. The changes of lymphocyte subsets were not significant in 9 patients with pulmonary oligometastasis. 0 to 7 days before radiotherapy and 0 to 7 days after radiotherapy, there was an increase in P0. 027 CD4 after radiotherapy and 0-7 days after radiotherapy compared with that before radiotherapy. After radiotherapy, there was an increase of P0. 032, P0. 032, and the proportion of other lymphocyte subsets in lung after radiotherapy. Conclusion SBRT treatment has no significant effect on pulmonary lung. The immune function of tumor patients was not affected. It can be considered as a safe and effective treatment for patients who are unable or unwilling to undergo surgery because of advanced age or severe heart disease. For patients with pulmonary oligometastasis, after SBRT treatment, In addition, SBRT treatment may cause local immune response of tumor. The specific detection of biological markers, detection methods and detection timing need to be further studied.
【學(xué)位授予單位】：鄭州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R734.2;R730.55

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 林嶺海;黃良喜;;�？颂婺岚邢蛑委煂�(duì)高齡非小細(xì)胞肺癌患者營(yíng)養(yǎng)及免疫功能的影響[J];中國(guó)藥業(yè);2016年16期

2 王小磊;劉微微;;�？颂婺岚邢蛑委煂�(duì)非小細(xì)胞肺癌患者血管內(nèi)皮生長(zhǎng)因子及免疫功能的影響[J];中國(guó)老年學(xué)雜志;2016年11期

3 Zhi-Mei Huang;Chang-Chuan Pan;Pei-Hong Wu;Ming Zhao;Wang Li;Zi-Lin Huang;Rui-Yang Yi;;Efficacy of minimally invasive therapies on unresectable pancreatic cancer[J];Chinese Journal of Cancer;2013年06期

4 陳明秋;徐本華;林慶良;李小波;;食管癌細(xì)胞免疫功能抑制及放射治療的影響[J];瀘州醫(yī)學(xué)院學(xué)報(bào);2008年06期

5 錢印榕;王福龍;王君;黃澤文;;42例胃腸道腫瘤患者手術(shù)前后細(xì)胞免疫功能的動(dòng)態(tài)檢測(cè)[J];臨床腫瘤學(xué)雜志;2007年09期

6 劉思海;朱瑞霞;吳曉阜;付正傳;高飛;;立體定向適形放射治療煤工塵肺合并肺癌對(duì)外周血細(xì)胞免疫功能影響[J];中國(guó)職業(yè)醫(yī)學(xué);2006年02期

7 高勁,程廣源;放射治療對(duì)肺癌患者細(xì)胞免疫功能的影響[J];臨床肺科雜志;2001年04期

，

本文編號(hào)：1699206